Adverse effects of systemic advanced melanoma therapies—do BRAF/MEK inhibitors increase the incidence of mesenteric panniculitis?
Question BRAF/MEK and immune checkpoint inhibitors have revolutionized melanoma treatment but are associated with various side effects, yet data regarding the development of mesenteric panniculitis are scarce. Findings BRAF/MEK inhibitor treatment is associated with a significantly higher rate of mesenteric panniculitis compared to immune checkpoint inhibitor treatment in advanced melanoma. Clinical relevance BRAF/MEK inhibitor-treated patients are at risk for development of mesenteric panniculitis. As this benign finding can mimic or conceal malignancy, awareness of it is important especially in these patients.
Authors
- Marcel Opitz (ORCID: https://orcid.org/0000-0001-7455-8590)
- M Drews (ORCID: https://orcid.org/0009-0003-9825-3136)
- Benedikt M. Schaarschmidt (ORCID: https://orcid.org/0000-0001-6331-7679)
- Johannes Haubold (ORCID: https://orcid.org/0000-0003-4843-5911)
- Dirk Schadendorf (ORCID: https://orcid.org/0000-0003-3524-7858)
- Elisabeth Livingstone (ORCID: https://orcid.org/0000-0001-8279-9239)
- Selma Ugurel (ORCID: https://orcid.org/0000-0002-9384-6704)
- Denise Bos (ORCID: https://orcid.org/0000-0002-9585-9787)
- Lisa Zimmer (ORCID: https://orcid.org/0000-0002-3680-3521)
- Sebastian Zensen (ORCID: https://orcid.org/0000-0003-2997-0740)
- Alexander Baumgarten
Institutions
- Essen University Hospital (DE)
Publication Details
- Journal
- European Radiology
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1007/s00330-025-11642-w
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00